Intermittent Preventive Treatment of Malaria in Pregnancy with Mefloquine in HIV-Infected Women Receiving Cotrimoxazole Prophylaxis: A Multicenter Randomized Placebo-Controlled Trial

English version České info

Background:
Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended for malaria prevention in HIV-negative pregnant women, but it is contraindicated in HIV-infected women taking daily cotrimoxazole prophylaxis (CTXp) because of potential added risk of adverse effects associated with taking two antifolate drugs simultaneously. We studied the safety and efficacy of mefloquine (MQ) in women receiving CTXp and long-lasting insecticide treated nets (LLITNs).

Methods and Findings:
A total of 1,071 HIV-infected women from Kenya, Mozambique, and Tanzania were randomized to receive either three doses of IPTp-MQ (15 mg/kg) or placebo given at least one month apart; all received CTXp and a LLITN. IPTp-MQ was associated with reduced rates of maternal parasitemia (risk ratio [RR], 0.47 [95% CI 0.27–0.82]; p = 0.008), placental malaria (RR, 0.52 [95% CI 0.29–0.90]; p = 0.021), and reduced incidence of non-obstetric hospital admissions (RR, 0.59 [95% CI 0.37–0.95]; p = 0.031) in the intention to treat (ITT) analysis. There were no differences in the prevalence of adverse pregnancy outcomes between groups. Drug tolerability was poorer in the MQ group compared to the control group (29.6% referred dizziness and 23.9% vomiting after the first IPTp-MQ administration). HIV viral load at delivery was higher in the MQ group compared to the control group (p = 0.048) in the ATP analysis. The frequency of perinatal mother to child transmission of HIV was increased in women who received MQ (RR, 1.95 [95% CI 1.14–3.33]; p = 0.015). The main limitation of the latter finding relates to the exploratory nature of this part of the analysis.

Conclusions:
An effective antimalarial added to CTXp and LLITNs in HIV-infected pregnant women can improve malaria prevention, as well as maternal health through reduction in hospital admissions. However, MQ was not well tolerated, limiting its potential for IPTp and indicating the need to find alternatives with better tolerability to reduce malaria in this particularly vulnerable group. MQ was associated with an increased risk of mother to child transmission of HIV, which warrants a better understanding of the pharmacological interactions between antimalarials and antiretroviral drugs.

Trial registration:
ClinicalTrials.gov NCT 00811421; Pan African Clinical Trials Registry PACTR 2010020001813440

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Intermittent Preventive Treatment of Malaria in Pregnancy with Mefloquine in HIV-Infected Women Receiving Cotrimoxazole Prophylaxis: A Multicenter Randomized Placebo-Controlled Trial. PLoS Med 11(9): e32767. doi:10.1371/journal.pmed.1001735
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001735

Souhrn

Trial registration:
ClinicalTrials.gov NCT 00811421; Pan African Clinical Trials Registry PACTR 2010020001813440

Please see later in the article for the Editors' Summary

Zdroje

1. GonzalezR, AtaideR, NanicheD, MenendezC, MayorA (2012) HIV and malaria interactions: where do we stand? Expert Rev Anti Infect Ther 10: 153–165.

2. ter KuileFO, PariseME, VerhoeffFH, UdhayakumarV, NewmanRD, et al. (2004) The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg 71: 41–54.

3. UnekeCJ, OgbonnaA (2009) Malaria and HIV co-infection in pregnancy in sub-Saharan Africa: impact of treatment using antimalarial and antiretroviral agents. Trans R Soc Trop Med Hyg 103: 761–767.

4. van EijkAM, AyisiJG, ter KuileFO, MisoreAO, OtienoJA, et al. (2003) HIV increases the risk of malaria in women of all gravidities in Kisumu, Kenya. AIDS 17: 595–603.

5. MayorA, KumarU, BardajiA, GuptaP, JimenezA, et al. (2013) Improved pregnancy outcomes in women exposed to malaria with high antibody levels against Plasmodium falciparum. J Infect Dis 207: 1664–1674.

6. MenendezC, D'AlessandroU, ter KuileFO (2007) Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect Dis 7: 126–135.

7. MenendezC, BardajiA, SigauqueB, RomagosaC, SanzS, et al. (2008) A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic. PLoS ONE 3: e1934.

8. WHO (2012) Intermittent Preventive Treatment of malaria in pregnancy using Sulfadoxine-Pyrimethamine (IPTp-SP). Updated WHO Policy Recommendation. WHO Available: http://www.who.int/malaria/iptp_sp_updated_policy_recommendation_en_102012.pdf

9. WHO (2004) A strategic framework for malaria prevention and control during pregnancy in the African region. Geneva: World Health Organization. AFR/MAL/04/01.

10. WHO (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Recommendations for a public health approach June 2013. Geneva: World Health Organization.

11. SeveneE, GonzalezR, MenendezC (2010) Current knowledge and challenges of antimalarial drugs for treatment and prevention in pregnancy. Expert Opin Pharmacother 11: 1277–1293.

12. WardSA, SeveneEJ, HastingsIM, NostenF, McGreadyR (2007) Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis 7: 136–144.

13. DaramolaOO, AlonsoPL, O'DempseyTJ, TwumasiP, McArdleTF, et al. (1991) Sensitivity of Plasmodium falciparum in The Gambia to co-trimoxazole. Trans R Soc Trop Med Hyg 85: 345–348.

14. AnglaretX, MessouE, OuassaT, ToureS, Dakoury-DogboN, et al. (2003) Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote d'Ivoire. AIDS 17: 575–584.

15. RamharterM, WernsdorferWH, KremsnerPG (2004) In vitro activity of quinolines against Plasmodium falciparum in Gabon. Acta Trop 90: 55–60.

16. UhlemannAC, RamharterM, LellB, KremsnerPG, KrishnaS (2005) Amplification of Plasmodium falciparum multidrug resistance gene 1 in isolates from Gabon. J Infect Dis 192: 1830–1835.

17. AubouyA, FievetN, BertinG, SagboJC, KossouH, et al. (2007) Dramatically decreased therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in southern Benin. Trop Med Int Health 12: 886–894.

18. CDC (2011) Update: new recommendations for mefloquine use in pregnancy. Available: http://www.cdc.gov/malaria/new_info/2011/mefloquine_pregnancy.html. Accessed July 2013.

19. FDA (2013) FDA Drug Safety Communication: FDA approves label changes for antimalarial drug mefloquine hydrochloride due to risk of serious psychiatric and nerve effects. Available: http://wwwfdagov/Drugs/DrugSafety/ucm362227htm. Accessed July 2013.

20. McGreadyR, ChoT, HkirijaroenL, SimpsonJ, ChongsuphajaisiddhiT, et al. (1998) Quinine and mefloquine in the treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy. Ann Trop Med Parasitol 92: 643–653.

21. BriandV, BotteroJ, NoelH, MasseV, CordelH, et al. (2009) Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. J Infect Dis 200: 991–1001.

22. Denoeud-NdamL, ClementMC, BriandV, AkakpoJ, AgossouVK, et al. (2012) Tolerability of mefloquine intermittent preventive treatment for malaria in HIV-infected pregnant women in Benin. J Acquir Immune Defic Syndr 61: 64–72.

23. Denoeud-NdamL, ZannouDM, FourcadeC, Taron-BrocardC, PorcherR, et al. (2014) Cotrimoxazole prophylaxis versus mefloquine intermittent preventive treatment to prevent malaria in HIV-infected pregnant women: two randomized controlled trials. J Acquir Immune Defic Syndr 65: 198–206.

24. van EijkAM, AyisiJG, ter KuileFO, OtienoJA, MisoreAO, et al. (2004) Effectiveness of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in western Kenya: a hospital-based study. Trop Med Int Health 9: 351–360.

25. GonzálezR, Mombo-NgomaG, OuédraogoS, KakolwaMA, AbdullaS, et al. (2014) Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-negative women: a multicentre randomized controlled trial. PLoS Med 11: e1001733.

26. Ministry of Health and Social Welfare-The United Republic of Tanzania (2007) National Guidelines Prevention of Mother-to-Child Transmission of HIV. Ministry of Health of The United Republic of Tanzania.

27. Ministry of Health-Republic of Kenya (2009) Guidelines for the prevention of Mother to Child transmission (PMTCT) of HIV/AIDS in Kenya. Ministry of Health-Kenya.

28. Ministério da Saúde-República de Moçambique (2013) Introduçao de Novas Normas para o seguimiento do paciente HIV positivo. Direcçao Nacional de Assistencia Médica Ministério da Saúde de Moçambique.

29. BallardJL, KhouryJC, WedigK, WangL, Eilers-WalsmanBL, et al. (1991) New Ballard Score, expanded to include extremely premature infants. J Pediatr 119: 417–423.

30. GreenwoodAM, ArmstrongJR, ByassP, SnowRW, GreenwoodBM (1992) Malaria chemoprophylaxis, birth weight and child survival. Trans R Soc Trop Med Hyg 86: 483–485.

31. PlancheT, KrishnaS, KombilaM, EngelK, FaucherJF, et al. (2001) Comparison of methods for the rapid laboratory assessment of children with malaria. Am J Trop Med Hyg 65: 599–602.

32. SwysenC, VekemansJ, BrulsM, OyakhiromeS, DrakeleyC, et al. (2011) Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. Malar J 10: 223.

33. AlonsoPL, SmithT, SchellenbergJR, MasanjaH, MwankusyeS, et al. (1994) Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 344: 1175–1181.

34. MayorA, Serra-CasasE, BardajiA, SanzS, PuyolL, et al. (2009) Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women. Malar J 8: 9.

35. OrdiJ, IsmailMR, VenturaPJ, KahigwaE, HirtR, et al. (1998) Massive chronic intervillositis of the placenta associated with malaria infection. Am J Surg Pathol 22: 1006–1011.

36. RogersonSJ, MkundikaP, KanjalaMK (2003) Diagnosis of Plasmodium falciparum malaria at delivery: comparison of blood film preparation methods and of blood films with histology. J Clin Microbiol 41: 1370–1374.

37. ZouG (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159: 702–706.

38. BardajiA, SigauqueB, BruniL, RomagosaC, SanzS, et al. (2008) Clinical malaria in African pregnant women. Malar J 7: 27.

39. TobinJ (1958) Estimation of relationships for limited dependent variables. Econometrica 26: 24–36.

40. Wooldridge JM (2012) Introductory econometrics: a modern approach. 5th edition. Cengage Learning.

41. WHO (2000) Safety monitoring of medicinal products. Guidelines for setting up and running a pharmacovigilance centre. WHO the Uppsala Monitoring Centre.

42. LadnerJ, LeroyV, SimononA, KaritaE, BogaertsJ, et al. (2002) HIV infection, malaria, and pregnancy: a prospective cohort study in Kigali, Rwanda. Am J Trop Med Hyg 66: 56–60.

43. RollinsNC, CoovadiaHM, BlandRM, CoutsoudisA, BennishML, et al. (2007) Pregnancy outcomes in HIV-infected and uninfected women in rural and urban South Africa. J Acquir Immune Defic Syndr 44: 321–328.

44. MenéndezC, RomagosaC, IsmailMR, CarrilhoC, SauteF, et al. (2008) An autopsy study of maternal mortality in Mozambique: the contribution of infectious diseases. PLoS Med 5: e44.

45. ZabaB, CalvertC, MarstonM, IsingoR, Nakiyingi-MiiroJ, et al. (2013) Effect of HIV infection on pregnancy-related mortality in sub-Saharan Africa: secondary analyses of pooled community-based data from the network for Analysing Longitudinal Population-based HIV/AIDS data on Africa (ALPHA). Lancet 381: 1763–1771.

46. SappenfieldE, JamiesonDJ, KourtisAP (2013) Pregnancy and susceptibility to infectious diseases. Infect Dis Obstet Gynecol 2013: 752852.

47. AlonsoPL, LindsaySW, Armstrong SchellenbergJR, KeitaK, GomezP, et al. (1993) A malaria control trial using insecticide-treated bed nets and targeted chemoprophylaxis in a rural area of The Gambia, west Africa. 6. The impact of the interventions on mortality and morbidity from malaria. Trans R Soc Trop Med Hyg 87 Suppl 2: 37–44.

48. NostenF, ter KuileF, MaelankiriL, ChongsuphajaisiddhiT, NopdonrattakoonL, et al. (1994) Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis 169: 595–603.

49. SchlagenhaufP, AdamcovaM, RegepL, SchaererMT, RheinHG (2010) The position of mefloquine as a 21st century malaria chemoprophylaxis. Malar J 9: 357.

50. SteketeeRW, WirimaJJ, SlutskerL, KhoromanaCO, HeymannDL, et al. (1996) Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Am J Trop Med Hyg 55: 50–56.

51. GonzalezR, HellgrenU, GreenwoodB, MenendezC (2014) Mefloquine safety and tolerability in pregnancy: a systematic literature review. Malar J 13: 75.

52. KhaliqY, GallicanoK, TisdaleC, CarignanG, CooperC, et al. (2001) Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. Br J Clin Pharmacol 51: 591–600.

53. Byakika-KibwikaP, LamordeM, MayitoJ, NabukeeraL, NamakulaR, et al. (2012) Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother 67: 2213–2221.

54. Byakika-KibwikaP, LamordeM, Okaba-KayomV, Mayanja-KizzaH, KatabiraE, et al. (2012) Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults. J Antimicrob Chemother 67: 1217–1223.

55. GermanP, ParikhS, LawrenceJ, DorseyG, RosenthalPJ, et al. (2009) Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr 51: 424–429.

56. KiangTK, WilbyKJ, EnsomMH (2014) Clinical Pharmacokinetic Drug Interactions Associated with Artemisinin Derivatives and HIV-Antivirals. Clin Pharmacokinet 53: 141–153.

57. KredoT, MauffK, Van der WaltJS, WiesnerL, MaartensG, et al. (2011) Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. Antimicrob Agents Chemother 55: 5616–5623.

58. BrachmanPSJr, MetchockB, KozarskyPE (1992) Effects of antimalarial chemoprophylactic agents on the viability of the Ty21a typhoid vaccine strain. Clin Infect Dis 15: 1057–1058.

59. HorowitzH, CarbonaroCA (1992) Inhibition of the Salmonella typhi oral vaccine strain, Ty21a, by mefloquine and chloroquine. J Infect Dis 166: 1462–1464.

60. AdachiE, KoibuchiT, ImaiK, KikuchiT, KogaM, et al. (2012) Favourable outcome of progressive multifocal leukoencephalopathy with mefloquine treatment in combination with antiretroviral therapy in an HIV-infected patient. Int J STD AIDS 23: 603–605.

61. GoftonTE, Al-KhotaniA, O'FarrellB, AngLC, McLachlanRS (2011) Mefloquine in the treatment of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry 82: 452–455.

62. MoensterRP, JettRA (2012) Mirtazapine and mefloquine therapy for progressive multifocal leukoencephalopathy in a patient infected with human immunodeficiency virus. Am J Health Syst Pharm 69: 496–498.

63. EzeamamaA, DugganC, ManjiK, SpiegelmanD, HertzmarkE, et al. (2014) Clinical malaria diagnosis in pregnancy in relation to early perinatal mother-to-child transmission of HIV: a prospective cohort study. HIV Med 15: 276–285.

64. UNAIDS/WHO (2010) Global report: UNAIDS report on the global AIDS Epidemic 2010. Joint United Nations Programme on HIV/AIDS UNAIDS/10.11E: (JC1958E).

65. WHO (2005) Technical Consultation on Malaria and HIV Interactions and Public Health Policy Implications (2004: Geneva, Switzerland) Malaria and HIV interactions and their implications for public health policy. Geneva: WHO.

66. MPAC (2013) Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2013 meeting. Malar J 12: 456.